Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy

Hoon Han Sang, Sik Chin Bum, Kyoung Choi Hee, Youn Shin So, Tae Chae Yun, Ji Hyeon Baek, Oh Kim Chang, Yong Choi Jun, Goo Song Young, Chul Lee Hyun, Myung Kim June

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lipoatrophy is the long-term adverse effects developed in human immunodeficiency virus (HIV)-1-infected subjects receiving highly active antiretroviral therapy (HAART). This cross-sectional study aimed to evaluate the prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving HAART for more than 6 months. Lipoatrophy was diagnosed by concordance between physical examination and history taking performed by a single physician. Various covariates were examined, including diabetes mellitus (DM), lipid profiles after HAART, and HAART regimen and duration. Among total 144 patients (6 females and 138 males), 35 patients (24.3%) were diagnosed with lipoatrophy. The prevalence of lipoatrophy was significantly higher in females than that in males [83.3% (5/6) vs. 21.7% (30/138), p = 0.010] and higher in patients with DM than patients without DM [66.7% (4/6 DM) vs. 22.5% (31/138 non-DM), p = 0.030], or in patients with high total cholesterol levels than patients with low total cholesterol levels [31.9% (23/72 patients with high cholesterol) vs. 16.7% (12/72 patients with low cholesterol), p = 0.035]. Moreover, patients with stavudine treatment history (> 12 months) had a higher prevalence of lipoatrophy than patients who never received stavudine [50.0% (15/30) vs. 16.5% (17/103), p < 0.001]. In the multivariate logistic analysis, stavudine treatment for > 12 months (OR, 3.67; p = 0.011) and being female (OR, 24.93; p = 0.009) are independently associated with lipoatrophy. In conclusion, the prevalence of lipoatrophy in HIV-infected Koreans receiving HAART is not uncommon. Limited use of stavudine and regular monitoring are warranted to reduce lipoatrophy.

Original languageEnglish
Pages (from-to)145-153
Number of pages9
JournalTohoku Journal of Experimental Medicine
Volume219
Issue number2
DOIs
Publication statusPublished - 2009 Nov 23

Fingerprint

Highly Active Antiretroviral Therapy
Medical problems
Stavudine
Viruses
Cholesterol
HIV
Diabetes Mellitus
Lipids
Monitoring
Hypercholesterolemia
Physical Examination
HIV-1
Cross-Sectional Studies
History
Physicians

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sang, Hoon Han ; Bum, Sik Chin ; Hee, Kyoung Choi ; So, Youn Shin ; Yun, Tae Chae ; Baek, Ji Hyeon ; Chang, Oh Kim ; Jun, Yong Choi ; Young, Goo Song ; Hyun, Chul Lee ; June, Myung Kim. / Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy. In: Tohoku Journal of Experimental Medicine. 2009 ; Vol. 219, No. 2. pp. 145-153.
@article{78190d4b488a410b83f87591eb5cce61,
title = "Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy",
abstract = "Lipoatrophy is the long-term adverse effects developed in human immunodeficiency virus (HIV)-1-infected subjects receiving highly active antiretroviral therapy (HAART). This cross-sectional study aimed to evaluate the prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving HAART for more than 6 months. Lipoatrophy was diagnosed by concordance between physical examination and history taking performed by a single physician. Various covariates were examined, including diabetes mellitus (DM), lipid profiles after HAART, and HAART regimen and duration. Among total 144 patients (6 females and 138 males), 35 patients (24.3{\%}) were diagnosed with lipoatrophy. The prevalence of lipoatrophy was significantly higher in females than that in males [83.3{\%} (5/6) vs. 21.7{\%} (30/138), p = 0.010] and higher in patients with DM than patients without DM [66.7{\%} (4/6 DM) vs. 22.5{\%} (31/138 non-DM), p = 0.030], or in patients with high total cholesterol levels than patients with low total cholesterol levels [31.9{\%} (23/72 patients with high cholesterol) vs. 16.7{\%} (12/72 patients with low cholesterol), p = 0.035]. Moreover, patients with stavudine treatment history (> 12 months) had a higher prevalence of lipoatrophy than patients who never received stavudine [50.0{\%} (15/30) vs. 16.5{\%} (17/103), p < 0.001]. In the multivariate logistic analysis, stavudine treatment for > 12 months (OR, 3.67; p = 0.011) and being female (OR, 24.93; p = 0.009) are independently associated with lipoatrophy. In conclusion, the prevalence of lipoatrophy in HIV-infected Koreans receiving HAART is not uncommon. Limited use of stavudine and regular monitoring are warranted to reduce lipoatrophy.",
author = "Sang, {Hoon Han} and Bum, {Sik Chin} and Hee, {Kyoung Choi} and So, {Youn Shin} and Yun, {Tae Chae} and Baek, {Ji Hyeon} and Chang, {Oh Kim} and Jun, {Yong Choi} and Young, {Goo Song} and Hyun, {Chul Lee} and June, {Myung Kim}",
year = "2009",
month = "11",
day = "23",
doi = "10.1620/tjem.219.145",
language = "English",
volume = "219",
pages = "145--153",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "2",

}

Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy. / Sang, Hoon Han; Bum, Sik Chin; Hee, Kyoung Choi; So, Youn Shin; Yun, Tae Chae; Baek, Ji Hyeon; Chang, Oh Kim; Jun, Yong Choi; Young, Goo Song; Hyun, Chul Lee; June, Myung Kim.

In: Tohoku Journal of Experimental Medicine, Vol. 219, No. 2, 23.11.2009, p. 145-153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy

AU - Sang, Hoon Han

AU - Bum, Sik Chin

AU - Hee, Kyoung Choi

AU - So, Youn Shin

AU - Yun, Tae Chae

AU - Baek, Ji Hyeon

AU - Chang, Oh Kim

AU - Jun, Yong Choi

AU - Young, Goo Song

AU - Hyun, Chul Lee

AU - June, Myung Kim

PY - 2009/11/23

Y1 - 2009/11/23

N2 - Lipoatrophy is the long-term adverse effects developed in human immunodeficiency virus (HIV)-1-infected subjects receiving highly active antiretroviral therapy (HAART). This cross-sectional study aimed to evaluate the prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving HAART for more than 6 months. Lipoatrophy was diagnosed by concordance between physical examination and history taking performed by a single physician. Various covariates were examined, including diabetes mellitus (DM), lipid profiles after HAART, and HAART regimen and duration. Among total 144 patients (6 females and 138 males), 35 patients (24.3%) were diagnosed with lipoatrophy. The prevalence of lipoatrophy was significantly higher in females than that in males [83.3% (5/6) vs. 21.7% (30/138), p = 0.010] and higher in patients with DM than patients without DM [66.7% (4/6 DM) vs. 22.5% (31/138 non-DM), p = 0.030], or in patients with high total cholesterol levels than patients with low total cholesterol levels [31.9% (23/72 patients with high cholesterol) vs. 16.7% (12/72 patients with low cholesterol), p = 0.035]. Moreover, patients with stavudine treatment history (> 12 months) had a higher prevalence of lipoatrophy than patients who never received stavudine [50.0% (15/30) vs. 16.5% (17/103), p < 0.001]. In the multivariate logistic analysis, stavudine treatment for > 12 months (OR, 3.67; p = 0.011) and being female (OR, 24.93; p = 0.009) are independently associated with lipoatrophy. In conclusion, the prevalence of lipoatrophy in HIV-infected Koreans receiving HAART is not uncommon. Limited use of stavudine and regular monitoring are warranted to reduce lipoatrophy.

AB - Lipoatrophy is the long-term adverse effects developed in human immunodeficiency virus (HIV)-1-infected subjects receiving highly active antiretroviral therapy (HAART). This cross-sectional study aimed to evaluate the prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving HAART for more than 6 months. Lipoatrophy was diagnosed by concordance between physical examination and history taking performed by a single physician. Various covariates were examined, including diabetes mellitus (DM), lipid profiles after HAART, and HAART regimen and duration. Among total 144 patients (6 females and 138 males), 35 patients (24.3%) were diagnosed with lipoatrophy. The prevalence of lipoatrophy was significantly higher in females than that in males [83.3% (5/6) vs. 21.7% (30/138), p = 0.010] and higher in patients with DM than patients without DM [66.7% (4/6 DM) vs. 22.5% (31/138 non-DM), p = 0.030], or in patients with high total cholesterol levels than patients with low total cholesterol levels [31.9% (23/72 patients with high cholesterol) vs. 16.7% (12/72 patients with low cholesterol), p = 0.035]. Moreover, patients with stavudine treatment history (> 12 months) had a higher prevalence of lipoatrophy than patients who never received stavudine [50.0% (15/30) vs. 16.5% (17/103), p < 0.001]. In the multivariate logistic analysis, stavudine treatment for > 12 months (OR, 3.67; p = 0.011) and being female (OR, 24.93; p = 0.009) are independently associated with lipoatrophy. In conclusion, the prevalence of lipoatrophy in HIV-infected Koreans receiving HAART is not uncommon. Limited use of stavudine and regular monitoring are warranted to reduce lipoatrophy.

UR - http://www.scopus.com/inward/record.url?scp=70449679037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449679037&partnerID=8YFLogxK

U2 - 10.1620/tjem.219.145

DO - 10.1620/tjem.219.145

M3 - Article

C2 - 19776532

AN - SCOPUS:70449679037

VL - 219

SP - 145

EP - 153

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 2

ER -